in this issue
Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients
FDA issues warning letter to RPG Life Sciences API plant in India
June 24, 2013 | Deepti Ramesh
FDA issued a warning letter late last month to the active pharmaceutical ingredient (API) and finished pharmaceutical manufacturing facilities of RPG Life Sciences (Mumbai)—located at Navi Mumbai and Ankleshwar, India, respectively—for violations of cGMP. The warning letter was recently published on the FDA Web site. An FDA inspections, from 28–31 January 2013 at the Navi Mumbai API facility and from 20–24 November 2012 at the Ankleshwar finished pharmaceuticals facility, identified significant deviations from cGMP for the manufacture of...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee